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Conservative treatments for tennis elbow—do subgroups of patients
respond differently?
L. Bisset1,2, N. Smidt3,4, D. A. Van der Windt5,6, L. M. Bouter5, G. Jull1, P. Brooks7 and B. Vicenzino1
Objectives. To determine if subgroups of patients with tennis elbow respond differently in treatment.
Methods. This study used individual patient data (n¼ 383) from two randomized controlled trials that investigated a wait-and-see policy,
corticosteroid injections and physiotherapy. Common outcome measures were: pain severity, global improvement, severity assessed by a
blinded assessor, elbow disability and pain free grip strength. Subgroup analyses for previous history of elbow pain, baseline pain severity,
duration of the current episode and employment status were performed at 6 and 52 weeks.
Results. Patients’ age, previous elbow symptoms and baseline pain severity were similar between trials, but other characteristics differed
between trial populations. Based on individual patient data from both trials, we found that corticosteroid injections were statistically and
clinically superior at 6 weeks, but significantly worse at 52 weeks compared with both wait-and-see and physiotherapy. Subgroup effects were
scarce and small. Patients with higher baseline pain score showed less benefit on pain outcomes between physiotherapy and a wait-and-see
policy at 6 weeks. It also appeared that non-manual workers who had an injection were the only work subgroup to follow the general trend that
injections were significantly worse than a wait-and-see policy on global improvement at 52 weeks.
Conclusion. The treatment outcomes were largely similar between trials and not different between most subgroups studied. In tennis elbow,
it would appear that patient characteristics play only a small role in predicting treatment outcomes, which supports the generalizability of
individual trial results.
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Introduction
Lateral epicondylalgia (tennis elbow) is a common musculoske-
letal condition [1–5], which is often treated by physiotherapy [6, 7],
corticosteroid injections [7–9] or by adopting a wait-and-see
policy. Two recent randomized controlled trials (RCTs) have
assessed these three interventions and found corticosteroid
injections to have a strong initial effect, but poorer long-term
outcomes [10, 11]. Smidt et al. [11] in a primary care RCT found a
physiotherapy approach of deep friction massage, ultrasound
and exercise gave no added benefit over a wait-and-see approach.
A recent RCT by Bisset et al. [10] found superior effects for a
physiotherapy intervention of ‘mobilization with movement’
of the elbow and therapeutic exercise in the short-term (6 weeks)
over a wait-and-see policy. In the long-term (52 weeks), both
studies found superior effects for physiotherapy compared with
corticosteroid injections, but no difference between physiotherapy
and a wait-and-see policy.
Whilst clinical trials provide insight into the efficacy of
interventions for the average population, the effects of treat-
ments may be different for patients with specific characteristics.
Previous authors have suggested that patients with greater pain
severity, longer duration, previous history of concomitant
neck and shoulder pain, manual work and involvement of the
dominant side, are associated with poorer outcomes [12–14]. It is
unclear if these factors indeed modify treatment effects.
Valuable information on patient characteristics that modify
treatment outcomes in tennis elbow may be gained through
subgroup analyses. However, subgroup analyses within a single
RCT are often hampered by insufficient statistical power to reveal
differences in treatment effects, as RCTs are usually only powered
to reveal differences between the intervention groups under
evaluation [15]. Pooling of individual patient data from more
than one RCT increases the statistical power, and thus the
possibility of identifying relevant subgroup effects [16].
The main aim of this study was to examine the influence of
certain population characteristics (e.g. duration of symptoms,
baseline pain severity) on the effect of conservative treatment in
patients with tennis elbow.
Methods
This study combines individual patient data from two pragmatic
RCTs that studied conservative management of clinically
diagnosed tennis elbow of >6 weeks duration. One of the RCTs,
conducted by Smidt et al. [11] recruited 185 patients from
259 potential candidates who were identified by general medical
practitioners in Amsterdam, Amstelveen, Alkmaar, Purmerend
and Haarlem (The Netherlands); whereas the other RCT under-
taken by Bisset et al. [10] recruited 198 patients from 497
responders to a public call for volunteer participants in the
Brisbane region (Australia). Thus, the combined data set had a
sample size of 383. Details regarding the selection and informed
consent procedures for each trial are described elsewhere. Ethical
approval for this study was obtained through the Medical
Research Ethics Committee of the University of Queensland
and all participants provided informed consent prior to
participation.
Both RCTs used similar inclusion and exclusion criteria. The
Dutch RCT accepted an age range of 18–70 yrs and the Australian
RCT had an age limit of 18–65 yrs. Furthermore, the Dutch
RCT excluded those who had had treatment of their elbow
symptoms with physiotherapy or injections in the preceding
6 months, whereas the Australian RCT excluded patients who
had had any treatment of the elbow pain by a health care
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practitioner within the preceding 6 months (pain medication,
braces or stretches excepted).
In both RCTs, patient characteristics were recorded prior to
randomization, including age, sex, employment status (manual,
non-manual, no work), duration of elbow symptoms and previous
episodes of elbow symptoms. Both RCTs utilized concealed
random allocation of participants to interventions and intention
to treat analysis.
Treatments
In the Dutch RCT, 64 patients were allocated to physiotherapy,
which consisted of nine treatments over 6 weeks of deep friction
massage, pulsed ultrasound [17] and a progressive exercise
programme [18], 62 patients received at least one (maximum of
three) local injection of 1ml triamcinolone acetonide with 1ml
lidocaine and 59 were treated according to a wait-and-see policy of
a single session with their family doctor where ergonomic advice
and medication (paracetamol or non-steroidal anti-inflammatory
drugs) were given. In the Australian RCT, 66 participants were
allocated to eight sessions (30min duration) of elbow manipula-
tion and exercise, 65 participants were assigned to the same
corticosteroid injection as used in the Dutch RCT but limited to a
maximum of two injections, and 67 participants were managed by
a wait-and-see approach (ergonomic advice, medication was not
given but allowed as required).
Outcome measures
For the combined analysis, we used the follow-up times of 6 and
52 weeks after randomization, as well as baseline prior to
randomization. The following outcome measures were employed
in both RCTs: global improvement, pain severity, pain-free grip
strength, blinded assessor’s rating of severity and elbow disability
on a pain-free function questionnaire. In both RCTs, global
improvement was measured on a six-point Likert scale (‘com-
pletely recovered’ to ‘much worse’) and a successful outcome was
qualified as those participants who rated themselves ‘completely
recovered’ or ‘much improved’.
There were some differences between the RCTs in the manner
in which the outcome measures were applied. In the Australian
RCT, pain severity and the blinded assessor’s rating of severity
was measured on a continuous visual analogue scale (0mm¼ no
pain, 100mm¼worst pain imaginable); whereas in the Dutch
RCT, an 11-point categorical scale (0¼ no pain, 10¼worst pain
imaginable) was used. The Dutch RCT used a modified Pain Free
Function Questionnaire [19] in which 10 items representing
common activities that may cause elbow pain were rated on a
five-point Likert scale (i.e. total possible score¼ 40), whereas
the Australian RCT used an 8-item dichomous scale (yes/no;
i.e. total possible score¼ 8) [19]. To standardize the score for
these questionnaires, the measures were transformed to 0–100
scales, where 100 indicates maximum severity [20]. The two RCTs
also used different instruments and different units of measure for
the evaluation of grip strength [Jamar hand dynamometer (kg) in
the Dutch and digital grip dynamometer (MIE Medical Research
Ltd, UK; Newtons) in the Australian], so pain-free grip strength
in the affected arm was expressed as a percent of maximum grip
strength of the unaffected arm; with a higher score indicating
better grip strength.
Statistical analyses
The data analysis used SPSS version 13.0 [21]. Homogeneity of
the study population was evaluated prior to the pooling of
individual patient data, using Student’s t-tests (continuous data)
and chi-squared tests (dichotomous data). The demographical
characteristics of the patient population included in this analysis
were age, sex, employment status (manual, non-manual, no work),
duration of elbow symptoms, dominant side affected and previous
elbow symptoms. The outcome measures assessed at baseline
were pain severity, assessor rating of severity, pain-free grip
strength, global improvement and elbow disability. Baseline
outcome measures that were not significantly different between
RCTs (P> 0.05) were used to evaluate the treatment effects
at 6 and 52 weeks’ follow-up for the following subgroups of
patients: pain severity at presentation (median split; <60mm
vs 60mm), duration of elbow complaints (median split;
14 weeks vs> 14 weeks), previous elbow complaints (yes vs no)
and employment status (manual work vs non-manual work vs
no work).
Firstly, interaction between treatment groups, trial and
subgroup variables was evaluated in order to determine if
treatment effects differed between RCTs and whether outcomes
in subgroups of patients were determined by trial and/or
treatment groups (P< 0.10). Secondly, because there was no
significant three-way interaction (P> 0.10) but a significant
treatment by subgroup interaction (P< 0.10), differences between
subgroups of patients within each treatment group were then
investigated using univariate analysis of covariance for continuous
outcomes and logistic regression for dichomous outcomes,
measured at 6 and 52 weeks’ follow-up. Trial and baseline
values for the outcome measure were retained in the model
as covariates.
Differences in treatment effects between subgroups of patients
were presented as mean difference and 95% confidence intervals
(CI) for continuous outcomes and relative risk (RR) and numbers
needed to treat (NNT) for dichotomous outcomes [22].
Results
Table 1 shows the demographic and clinical patient character-
istics and outcome measures for both RCTs at baseline. The
populations were similar with respect to age and previous
history of elbow symptoms. However, more men were included
in the Australian (65%) than in the Dutch RCT (50%).
Patients in the Australian RCT had on average a longer duration
of elbow complaints than the patients in the Dutch RCT (mean
difference 13.2 weeks; 95% CI 7.5–18.8), but patients in
the Dutch RCT reported more elbow complaints on the dominant
side than in the Australian RCT (mean difference 11%; 95%
CI 2–20).
Except for pain severity at baseline, all outcome values at
baseline were significantly different between RCTs. Differences
between baseline outcomes could not be explained by differences
in patient characteristics between the two RCTs (Table 1).
Therefore, the outcome measures of global improvement, which
was not measured at baseline, and pain severity were used to
evaluate the treatment effects in subgroups of patients.
The population characteristics did not significantly influence
outcomes over time. There were no significant differences in
treatment effects between RCTs for pain severity at 6 or 52 weeks,
however, there was a significant difference between RCTs for
global improvement at 6 weeks (P¼ 0.014), but not at 52 weeks.
Therefore, the individual patient data from both RCTs were used
to assess the combined treatment effects on pain severity at 6 and
52 weeks and for global improvement at 52 weeks.
Despite differences in patient characteristics at baseline, the
overall pattern of treatment effects were very similar for both
RCTs. For the combined individual patient data at 6 weeks,
the corticosteroid injections group was significantly superior to
both the physiotherapy and the wait-and-see policy for pain
severity and global improvement scores. The physiotherapy group
was also significantly superior to the wait-and-see (Figs 1 and 2,
Table 2). This relative success was not present at 52 weeks, with
injection significantly worse than both physiotherapy and the
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wait-and-see policy in the long-term (Table 2, Figs 1 and 2).
At 52 weeks, physiotherapy remained significantly better than
wait-and-see for pain severity, but not global improvement
(Table 2). There were significant differences in treatment effects
for the subgroup of baseline pain severity at 6 weeks, with a
smaller and non-significant benefit of physiotherapy over the
wait-and-see group for those patients reporting baseline pain
>60mm (Table 2), compared with those with lower baseline pain
scores who received the physiotherapy treatment. There was also a
significant interaction between treatment and the employment
subgroups for global improvement at 52 weeks (P¼ 0.055).
Specifically, only in non-manual workers was the success rate
with corticosteroid injection significantly worse when compared
with wait-and-see.
Discussion
From this analysis of individual patient data from two RCTs,
it was readily apparent that corticosteroid injection treatment
provides superior short-term (6 weeks) results but at the cost
of significantly worse outcomes than wait-and-see or physiother-
apy in the long-term (1 yr). At 52 weeks, the majority of
participants in both the wait-and-see and physiotherapy groups
reported a successful outcome (87% wait-and-see, 92% phy-
siotherapy). Although physiotherapy appears to accelerate the
recovery over a wait-and-see policy in the short-term and
remained significantly superior to the wait-and-see policy in
the long-term for the measure of pain severity, the size of this
effect (VAS of 10 and 6/100mm, respectively) is of questionable
clinical relevance.
The overall effects observed in the combined individual
patient data from the two RCTs were not substantially altered
in the subgroup analyses. That is, our study did not find that
patient characteristics modified treatment effects in the short or
long-term, except for small effects of baseline pain severity on
pain outcome at 6 weeks and employment status on global
improvement outcome at 52 weeks (Table 2). In the short-term it
would appear that those patients receiving physiotherapy who
report more severe pain at baseline (60mm) may not respond
significantly better when compared with wait-and-see and
clinicians may need to focus initially more on pain relieving
techniques or modalities. Only in non-manual workers were
the success rates in those receiving corticosteroid injections
significantly lower when compared with wait-and-see. This is
difficult to explain and given the number of analyses, may be
a chance finding. Alternatively, manual workers—if they take
sick leave—and those without work may give their elbow
more rest, or alternatively, this may reflect a protective
function of those engaging in incidental physical activity after
injection. Further investigation is required to evaluate
these assertions.
There are dangers inherent in performing subgroup analyses in
a single RCT. In particular, there is a risk of performing multiple
and possibly excessive analyses in order to uncover some effect of
the target intervention, albeit in a subgroup of the trial
population, i.e. data dredging [15]. Also, there may be insufficient
statistical power to reveal differences within a single RCT, because
the trial is usually only powered to reveal differences between
intervention groups. We have endeavoured to address these issues
by defining in advance the factors upon which to subgroup the
study population and furthermore we pooled individual patient
data from two RCTs. Nevertheless, the effects we report are small
and should be interpreted with care.
Despite the clinical heterogeneity between the two RCT
populations, patterns of treatment effects over time were very
similar between RCTs. This suggests that the treatment effects
are robust across an international population of patients
with tennis elbow, which is a similar finding to that of Smidt
et al. [20], who compared the Dutch RCT data with that from the
one in the UK.
A potential source of heterogeneity between the two RCTs was
the difference in recruitment of the patient populations. The
Dutch RCT recruited patients who had visited a general medical
practitioner for their elbow condition, while the Australian RCT
recruited patients from the general community. Interestingly,
Hudak et al. [13] recommended a wider spectrum of patients than
just those referred from general medical practice be used in studies
of tennis elbow so as to improve the information gained on clinical
course and prognosis of outcome. The influence of source of
participants on baseline population characteristics and treatment
outcomes should be further assessed.
From the combined individual patient data of two RCTs
comparing physiotherapy, corticosteroid injections and wait-
and-see policy interventions, in the main, it appears that
subgroups of patients determined by baseline patient character-
istics do not differ on outcomes over time. However, baseline
severity of pain appears to modify the effects of physiotherapy in
the short-term and clinicians may expect weaker effects for
physiotherapy treatment in the short-term in patients reporting
high pain scores on initial assessment. Pooling of individual
patient data was possible despite population heterogeneity
between RCTs. This supports the generalizability of individual
RCT results.
TABLE 1. Participant characteristics and measures at baseline in two randomized controlled trials on conservative treatment of tennis elbow
Smidt et al. [11] (n¼185) Bisset et al. [10] (n¼198) Between-trial difference (95% CI)a Adjusted difference (95% CI)b
Baseline participant characteristics
Age in years 47.62 (9.5) 47.64 (7.8) 0.01 (1.8 to 1.7)
Female (%) 93 (50) 70 (35) 0.15 (0.05 to 0.24)
Employment status
Manual (%) 46 (25) 69 (35) 0.10 (0.19 to 0.01)
Non-manual (%) 77 (42) 98 (49) 0.08 (0.18 to 0.02)
No work (%) 62 (33) 31 (16) 0.18 (0.09 to 0.26)
Duration of elbow symptoms in weeks 17.73 (27.1) 30.01 (29.2) 13.2 (18.8 to 7.5)
Dominant side affected 145 (78) 133 (67%) 0.11 (0.02 to 0.20)
Previous elbow symptoms 58 (31) 55 (28%) 0.04 (0.06 to 0.13)
Baseline outcome measures
Pain VAS (/100) 54.32 (21.1) 57.47 (23.7) 3.2 (7.7 to 1.4) 2.7 (8.7 to 3.4)
Pain-free grip strength ratio 33.87 (21.6) 42.89 (20.0) 9 (13 to 4.8) 8.8 (13.2 to 4.5)
Pain-free function questionnaire (/100) 48.18 (16.9) 77.59 (19.0) 29.4 (33 to 25.8) 29.2 (33 to 25.5)
Assessor severity rating (/100) 67.41 (20.4) 53.80 (18.8) 13.60 (9.7 to 17.5) 13.9 (9.7 to 18.0)
Trial means (S.D.) and between-trial mean differences (95% CI) for continuous variables; number (percentages) and absolute risk (95% CI) for categorical variables.
aDutch trial minus the Australian trial, a positive score indicates higher figures in the Dutch trial.
bAdjusted between-trial mean differences, where appropriate, for gender, employment, duration of elbow symptoms and dominant side affected (P< 0.10).
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TABLE 2. Subgroup results and between-group comparisons in the pooled data set of two randomized controlled trials on conservative treatment of tennis elbow
Outcome measures Subgroups
Wait and see Corticosteroid injection Physiotherapy Mean difference (95% CI)
Mean S.D. Mean S.D. Mean S.D. Injection—wait-and-see PT—wait-and-see Injection—PT
PVAS 6 Weeks Pooled 44.1 (26.1) 13.3 (18.9) 33.8 (24.1) 30.4 (25.2 to 35.6)a 10.1 (4.9 to 15.3)b 20.3 (15.2 to 25.4)a
Baseline pain 60mmc
<60mm (n¼180) 35.3 (21.6) 9.8 (12.0) 21.8 (18.3) 25.8 (19.7 to 31.8) 12.9 (6.7 to 19.0) 12.9 (6.9 to 18.9)
60mm (n¼ 193) 52.0 (27.4) 16.8 (23.5) 44.5 (23.8) 34.7 (26.4 to 43.1) 7.7 (-0.5 to 15.9) 27.0 (18.8 to 35.3)
Duration
14 weeks (n¼188) 40.4 (24.4) 9.7 (13.5) 32.6 (24.0) 29.1 (22.3 to 36.0) 8.9 (2.2 to 15.7) 20.2 (13.6 to 26.8)
>14 weeks (n¼185) 47.5 (27.4) 16.8 (22.7) 35.1 (24.4) 31.5 (23.5 to 39.5) 10.8 (2.7 to 18.9) 20.6 (12.5 to 28.8)
Previous history
No (n¼263) 43.1 (25.2) 12.3 (16.6) 33.4 (25.2) 32.3 (26.0 to 38.6) 10.9 (4.8 to 17.0) 21.4 (15.4 to 27.5)
Yes (n¼110) 46.3 (28.2) 15.1 (22.7) 35.2 (20.5) 25.4 (15.6 to 35.2) 7.2 (3.5 to 17.9) 18.2 (7.8 to 28.5)
Employment status
Manual (n¼108) 47.1 (26.7) 15.3 (21.4) 38.7 (27.1) 27.8 (17.3 to 38.3) 8.3 (2.2 to 18.7) 19.6 (8.9 to 30.2)
Non-manual (n¼172) 42.4 (25.6) 11.1 (16.4) 31.4 (23.3) 31.9 (24.4 to 39.3) 9.7 (2.4 to 16.9) 22.2 (15.0 to 29.5)
No work (n¼93) 43.6 (26.9) 14.7 (19.9) 33.0 (21.9) 30.0 (19.2 to 40.8) 12.4 (1.2 to 23.6) 17.6 (7.0 to 28.2)
PVAS 52 Weeks Pooled 13.5 (21.5) 21.2 (26.9) 7.4 (15.7) 7.9 (13.3 to 2.4)d 6.0 (0.6 to 11.4)b 13.9 (19.3 to 8.5)b
Baseline pain 60mm
<60mm (n¼180) 10.7 (19.4) 16.1 (22.5) 7.2 (14.5) 5.2 (12.1 to 1.7) 3.3 (3.6 to 10.3) 8.5 (15.3 to 1.7)
60mm (n¼ 193) 16.0 (23.2) 26.2 (30.1) 7.6 (16.8) 10.1 (18.5 to 1.8) 8.6 (0.4 to 16.8) 18.7 (27.0 to 10.5)
Duration
14 weeks (n¼191) 12.0 (18.7) 20.4 (26.7) 7.3 (16.3) 9.2 (16.5 to 1.8) 5.0 (2.3 to 12.2) 14.1 (21.3 to 6.9)
>14 weeks (n¼182) 15.0 (24.1) 22.0 (27.3) 7.5 (15.1) 6.9 (14.9 to 1.1) 7.6 (0.6 to 15.8) 14.5 (22.7 to 6.4)
Previous history
No (n¼261) 12.9 (20.1) 19.1 (26.6) 5.7 (13.3) 5.8 (12.1 to 0.4) 7.5 (1.4 to 13.5) 13.3 (19.3 to 7.3)
Yes (n¼112) 14.7 (24.6) 25.2 (27.3) 12.7 (21.1) 14.2 (25.0 to -3.3) 0.5 (11.2 to 12.2) 13.6 (25.0 to 2.3)
Employment status
Manual (n¼108) 13.7 (23.8) 18.7 (28.2) 5.8 (14.7) 6.0 (16.7 to 4.8) 7.7 (3.1 to 18.6) 13.7 (25.0 to 2.4)
Non-manual (n¼172) 11.2 (17.5) 21.7 (25.2) 8.2 (15.8) 10.5 (18.0 to 3.1) 2.3 (4.9 to 9.6) 12.9 (20.0 to 5.7)
No work (n¼93) 17.6 (25.0) 22.9 (28.8) 7.4 (17.0) 4.3 (16.2 to 7.5) 12.1 (0.3 to 24.4) 16.4 (28.0 to 4.8)
Outcome measures
Wait-and-see Corticosteroid injection Physiotherapy Injection—wait-and-see PT—wait-and-see Injection—PT
n/N (%) n/N (%) n/N (%) RR (95% CI) NNT RR (95% CI) NNT RR (95% CI) NNT
SUCCESS 6 Weeks Dutch 19/59 (32) 57/62 (92) 30/64 (47) 2.86 (1.96–4.16)a 2 1.46 (0.93–2.29) 7 1.96 (1.50–2.57)a 2
Australia 16/60 (27) 51/65 (79) 41/63 (65) 2.94 (1.90–4.56)a 2 2.44 (1.55–3.85)b 3 1.21 (0.97–1.50) 7
SUCCESS 52 Weeks Pooled 105/121 (87) 87/125 (70) 117/127 (92) 0.80 (0.70-0.92)b 6 1.06 (0.97–1.16) 19 0.76 (0.67–0.86) 4
Baseline pain 60mm
<60mm (n¼ 179) 51/57 (90) 45/62 (73) 54/60 (90) 0.81 (0.68–0.97) 6 1.01 (0.89–1.14) 190 0.81 (0.68–0.96) 6
60mm (n¼194) 54/64 (84) 42/63 (67) 63/67 (94) 0.79 (0.64–0.97) 6 1.11 (0.99–1.26) 10 0.71 (0.59–0.85) 4
Duration
14 weeks (n¼191) 52/60 (87) 45/63 (71) 56/68 (82) 0.82 (0.69–0.99) 7 0.95 (0.82–1.10) 23 0.87 (0.72–1.05) 9
>14 weeks (n¼182) 53/61 (87) 42/62 (68) 52/59 (88) 0.78 (0.64–0.95) 5 1.01 (0.89–1.16) 80 0.77 (0.63–0.94) 5
Previous history
No (n¼261) 70/82 (85) 59/82 (72) 91/97 (94) 0.84 (0.72–0.99) 7 1.10 (0.99–1.22) 12 0.77 (0.66–0.89) 5
Yes (n¼112) 35/39 (90) 28/43 (65) 26/30 (87) 0.73 (0.57–0.93) 4 0.97 (0.81–1.15) 33 0.75 (0.58–0.97) 5
Employment status
Manual (n¼ 109) 33/40 (83) 28/35 (80) 32/34 (94) 1.03 (0.83–1.28) 40 1.14 (0.97–1.35) 9 0.85 (0.71–1.02) 7
Non-manual (n¼ 171) 49/53 (93) 34/55 (62) 56/63 (89) 0.67 (0.54–0.83)c 3 1.04 (0.93–1.17) 28 0.70 (0.56–0.87)b 4
No work (n¼ 93) 23/28 (82) 25/35 (71) 29/30 (97) 0.87 (0.66–1.14) 9 1.19 (0.98–1.42) 7 0.74 (0.59–0.92)b 4
Group means (S.D.) and between-group mean differences (95% CI) for pain (PVAS); and proportions (%) and between-group relative risks (95% CI) for global improvement (GI). PVAS adjusted for baseline pain score and trial and global improvement adjusted for
trial.
Pooled results: ain favour of corticosteroid injection, bin favour of physiotherapy, csignificant differences between treatments for subgroups, din favour of wait-and-see, P<0.05.
PT, physiotherapy; Injection, corticosteroid injection.
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FIG. 1. Pain severity for physiotherapy, corticosteroid injection and wait-and-see
policy in the pooled data set of two randomized controlled trials on conservative
treatment of tennis elbow.
FIG. 2. Global improvement (success) for physiotherapy, corticosteroid and wait-
and-see policy in the pooled data set of two randomized controlled trials on
conservative treatment of tennis elbow.
Rheumatology key messages
 Patient characteristics only minimally influence the outcomes of
different treatments.
 The clinician can rely on results of individual trials to predict
treatment outcome.
Conservative treatments for tennis elbow 1605
 at Vrije Universiteit - Library on July 19, 2011
rheum
atology.oxfordjournals.org
D
ow
nloaded from
 
